Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of pre-clinical development in the areas of immuno-oncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and anti-viral applications. Secarna’s mission is to maximize theperformance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, to develop highly specific, safe, and efficacious antisense therapies for challenging or currently not druggable targets.